factual
Hillhouse incubated de novo businesses and entered biotech
Hillhouse Capital evolved from a China-only long-only public equity manager in 2005 into a global investor that incubated de novo businesses and became a leading biotech investor, with the first four or five CFDA-approved drugs in China including at least three backed by the firm.
factualpending
Speaker
RickEvidence Quote
“if you look at the first four or five drugs that got CFDA approval in China, Hillhouse was behind at least three of them, and that was all in a matter of 10 years”
Source
Rick Buhrman & Paul Buser - Find Your X, Nurture Your N - [Invest Like the Best, EP.346]— Invest Like the BestCreated: 11/18/2026, 11:38:41 PM
Your notes
Loading notes...